MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (mnc pharma)
- GSK PHARMA
GSK PHARMA Share Price (GLXO)
Here is the latest stock price and chart of GSK Pharma. For more details, see the GSK Pharma company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
30th Oct, 6PM: Webinar teaching How to Ride India's Economic Recovery
| Live BSE Quotes | Oct 29, 2020 10:38:00 AM | ||
|---|---|---|---|
| Price (Rs)1,480.05 | Open (Rs) 1,499.70 | High (Rs) 1,499.70 | Low (Rs) 1,470.00 |
| % Change-1.30 | Volume 979 | Value (Rs) 1,448,969 | 52-Week H/L 1,805.00 / 1,046.40 |
| Live NSE Quotes | Oct 29, 2020 10:39:50 AM | ||
|---|---|---|---|
| Price (Rs)1,481.55 | Open (Rs) 1,480.00 | High (Rs) 1,489.95 | Low (Rs) 1,468.05 |
| % Change-1.15 | Volume 11,701 | Value (Rs) 17,288,462 | 52-Week H/L 1,807.50 / 962.65 |
| Change | |||||
|---|---|---|---|---|---|
| 1 Day -1.30% | 1 Month -5.89% | 3 Months -0.13% | 1 Year -7.16% | 5 Years (CAGR)* -2.03% | 10 Years (CAGR)* 2.90% |
* Compound Annual Growth Rate
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 6.35 | P/E Ratio (x) 233.13 | Market Cap (Rs m) 250,729.35 | P/BV (x) 11.72 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX 
PERIOD - Advanced Charts new
- Charts by TradingView
GSK PHARMA Share Price Today:
GSK PHARMA share price is down 1.3% to Rs 1,480.1 on the BSE. On the NSE, the GSK PHARMA share price is down 1.1% to Rs 1,481.6. The total volume of shares traded is 0.0 m.
Overall, the broader S&P BSE HEALTHCARE Index is trading down by 0.1%. And the benchmark S&P BSE SENSEX is at 39,722.0 (down 0.5%).
Over the last 30 days, the GSK PHARMA share price is down 6.1%. And over the last one year, GSK PHARMA share price is down 4.6%.
What else is happening in the markets today? Dig in...
- TRACK NOW:
- Most Active Stocks Rs 0 to 10
- Most Active Stocks Rs 10 to 20
- Top Gainers Today BSE A Group
- Top Gainers Today NSE Above Rs 20
- Top Gainers Today BSE Above Rs 20
- Top Gainers Today BSE Sensex
- Top Gainers Today BSE Small Cap
- Top Gainers Today BSE 500
- Top Losers Today BSE A Group
- Most Active Stocks Rs 1 to 2
- Top Losers Today NSE Above Rs 20
- Buzzing Stocks Today
- Most Popular Stocks BSE 30
Today's Market
Sensex Opens Lower Tracking Weak Global Cues; L&T Slips 4% Post Q2 Results(09:30 am)
Asian share markets are trading on a negative note today. The Nikkei is trading down by 0.7% and the Hang Seng is trading lower by 1%.
Related Views On News
GSK PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 2.2% (Quarterly Result Update)
Aug 26, 2020 | Updated on Aug 26, 2020For the quarter ended June 2020, GSK PHARMA has posted a net profit of Rs 1 bn (down 2.2% YoY). Sales on the other hand came in at Rs 6 bn (down 17.7% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)
Oct 25, 2019 | Updated on Oct 25, 2019For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Jun 24, 2019 | Updated on Jun 24, 2019Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.
More Views on NewsMost Popular
My View on ITC (Fast Profits Daily)
Oct 23, 2020What do the charts say about ITC?
PSU Banks Will Move Up Again (Profit Hunter)
Oct 27, 2020My charts tell me PSU banks are set for a rebound.
One of the Best Investment Opportunities in the Market Right Now (Fast Profits Daily)
Oct 16, 2020The one sector that you should be looking at to make good profits.
Why India's Drone Revolution is a 4x Profit Opportunity (Profit Hunter)
Oct 16, 2020My research on India's leading defence companies brought me to one major player in drone manufacturing.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2021
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
TRACK GSK PHARMA
- Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON GSK PHARMA
GSK PHARMA - ALEMBIC PHARMA COMPARISON
COMPARE GSK PHARMA WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.